Kahimmune Therapeutics Secures Exclusive License for Dark Genome Cancer Vaccine Platform
核心洞察
Kahimmune Therapeutics (搜索) has signed an exclusive licensing agreement with Gustave Roussy (搜索) and SATT Paris-Saclay (搜索) for its dark genome-based cancer vaccine platform, targeting previously unexplored non-coding DNA regions.
The company is developing shared mRNA cancer vaccines using novel tumor antigens called Kahigens (搜索), with its first candidate KAH-001 (搜索) targeting colorectal and pancreatic cancers.
A seed funding round is underway with a target of €8 million, with €3 million expected by the end of 2026, as the company advances toward clinical development.
Kahimmune Therapeutics (搜索), a newly established biotechnology company, has secured exclusive licensing rights to a novel cancer vaccine platform that targets the "dark genome" – the vast non-coding regions of DNA that comprise roughly 98% of human genetic material. The company announced the agreement with Gustave Roussy (搜索), Europe's leading cancer center, and SATT Paris-Saclay (搜索) in February 2026.
The licensing deal grants Kahimmune exclusive access to the core technology underlying its Kahinomics discovery platform, along with an initial set of tumor antigens identified through this approach, termed Kahigens (搜索). These assets originated from more than 15 years of research conducted by Dr. Sébastien Apcher, an Inserm scientist and group leader of the Non-conventional Epitopes Cancer Immune Responses unit at Gustave Roussy (搜索).
Targeting the Unexplored Cancer Immunopeptidome
The company's approach builds on research into Pioneer Translation Products (搜索) (PTPs) – peptides produced through non-standard translation processes that can still be recognized by the immune system. This work has demonstrated that regions of the genome traditionally labeled as "non-coding" can nonetheless give rise to immunogenic peptides detectable by the immune system, expanding the cancer immunopeptidome beyond conventional protein-coding genes.
"Kahigens (搜索) will provide the advantage to be new and to be specifically associated to a response to a cancer therapy, making them therapy-specific neoantigens, instead of cancer type-specific neoantigens, bringing synergy and better outcomes to patients," explained Philippe Villain-Guillot, Kahimmune's founder and CEO.
The dark genome approach addresses a significant gap in cancer research. While only 1% to 2% of human DNA encodes conventional proteins, the remaining non-coding regions have historically been less explored from an antigen-discovery perspective. Recent technological advances, including improved ribosome profiling and more sensitive mass spectrometry, have made it possible to detect antigens that would have gone unnoticed using earlier, protein-centric methods.
Development Pipeline and Clinical Focus
Kahimmune intends to develop shared mRNA cancer vaccines using these novel antigens, with its first program focused on colorectal and pancreatic cancer (搜索). The company is currently working on the design of the mRNA-LNP structure of its first cancer vaccine candidate, KAH-001 (搜索), with the final structure expected to be selected within 12 to 18 months.
The clinical rationale for targeting these cancers is compelling. According to WHO data cited by the company, colorectal cancer (搜索) is currently the third most diagnosed cancer and the second leading cause of cancer-related deaths worldwide, with 1.9 million new cases and 900,000 deaths annually. These figures are projected to grow by more than 70% and 90% respectively by 2050.
Pancreatic cancer (搜索), while ranked 13th in most diagnosed cancers with more than 510,000 new cases per year, has an extremely poor prognosis and represents the sixth leading cause of cancer-related deaths, with more than 467,000 deaths annually. Projections indicate growth of more than 65% and 70% respectively by 2050.
Funding and Strategic Positioning
The company has launched a seed funding round targeting €8 million, with a first tranche of €3 million expected by the end of 2026. "The company plans to contact venture capital funds, family offices, and business angel networks," said Villain-Guillot.
Kahimmune has positioned its vaccines as combination therapies, though it has not yet disclosed specific partner drugs or pharmaceutical collaborators. The company's longer-term strategy involves licensing pipeline assets or creating partnerships with pharmaceutical and biotechnology companies interested in its approach.
Competitive Landscape and Market Context
The dark genome approach represents a niche but emerging area in cancer vaccine development. Companies like UbiVac (搜索) have positioned their approach around what they describe as cancer's "dark matter," focusing on cryptic antigens detected through immune profiling. However, earlier attempts in this space, such as Vaxon Biotech's shared vaccines based on cryptic peptides, faced challenges when their candidate failed to meet primary endpoints in phase 2 trials.
The broader therapeutic cancer vaccine field has regained momentum, with encouraging signals including Moderna and Merck (搜索)'s positive five-year follow-up data for their personalized mRNA vaccine in melanoma (搜索), and UK-based Infinitopes (搜索) closing a $35 million seed round, both reported in January.
"Creating Kahimmune further demonstrates our capacity to enhance the leading scientific work coming out of public cancer research," said Christophe Javaud, head of the Technology Transfer Office at Gustave Roussy (搜索) Transfert. "This approach is particularly innovative because it explores the cancer immunopeptidome in developing next-generation immuno-oncology therapies."
The technology transfer was supported through a maturation program led by SATT Paris-Saclay (搜索), which has invested €58 million in commercialization since 2014, funding more than 180 innovative projects and creating 43 start-ups.